Guo, W.; Liang, D.; Wang, P.; Yin, L.; Zhang, H.; Xing, C.; Huang, Z.; Wu, Y.; Li, H.; Cheng, Z.;
et al. HIF-PH Encoded by EGLN1 Is a Potential Therapeutic Target for Chronic Lymphocytic Leukemia. Pharmaceuticals 2022, 15, 734.
https://doi.org/10.3390/ph15060734
AMA Style
Guo W, Liang D, Wang P, Yin L, Zhang H, Xing C, Huang Z, Wu Y, Li H, Cheng Z,
et al. HIF-PH Encoded by EGLN1 Is a Potential Therapeutic Target for Chronic Lymphocytic Leukemia. Pharmaceuticals. 2022; 15(6):734.
https://doi.org/10.3390/ph15060734
Chicago/Turabian Style
Guo, Wancheng, Daomiao Liang, Peilong Wang, Le Yin, Huifang Zhang, Cheng Xing, Zineng Huang, Yinghua Wu, Heng Li, Zhao Cheng,
and et al. 2022. "HIF-PH Encoded by EGLN1 Is a Potential Therapeutic Target for Chronic Lymphocytic Leukemia" Pharmaceuticals 15, no. 6: 734.
https://doi.org/10.3390/ph15060734
APA Style
Guo, W., Liang, D., Wang, P., Yin, L., Zhang, H., Xing, C., Huang, Z., Wu, Y., Li, H., Cheng, Z., Xiao, X., Liu, J., Wang, Z., & Peng, H.
(2022). HIF-PH Encoded by EGLN1 Is a Potential Therapeutic Target for Chronic Lymphocytic Leukemia. Pharmaceuticals, 15(6), 734.
https://doi.org/10.3390/ph15060734